FY2024 EPS Forecast for scPharmaceuticals Lowered by Analyst

scPharmaceuticals Inc. (NASDAQ:SCPH) – Research analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for scPharmaceuticals in a report issued on Thursday, November 14th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($1.43) per share for the year, down from their prior forecast of ($1.33). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for scPharmaceuticals’ Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.45 EPS.

Separately, Craig Hallum lowered their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

scPharmaceuticals Stock Up 5.1 %

scPharmaceuticals stock opened at $3.52 on Monday. The company has a market capitalization of $176.14 million, a P/E ratio of -1.85 and a beta of 0.15. The firm’s fifty day simple moving average is $4.39 and its 200-day simple moving average is $4.46. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals has a 1-year low of $3.08 and a 1-year high of $6.71.

Hedge Funds Weigh In On scPharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can bought a new position in scPharmaceuticals during the 2nd quarter valued at about $1,544,000. King Luther Capital Management Corp lifted its holdings in scPharmaceuticals by 51.8% during the 2nd quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock valued at $9,592,000 after purchasing an additional 752,005 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in shares of scPharmaceuticals by 76.9% in the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock worth $2,163,000 after acquiring an additional 216,122 shares during the last quarter. AIGH Capital Management LLC raised its stake in shares of scPharmaceuticals by 3.4% in the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock worth $15,244,000 after acquiring an additional 115,206 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of scPharmaceuticals by 266.7% in the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after acquiring an additional 52,870 shares during the last quarter. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.